The terms, per the grant. On October 13, 2020, Merck Sharp & Dohme was issued US10800826B2, "Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors." The CPC stack — C07K 14/605, A61K 47/6811 and A61K 47/6843 (peptide-to-antibody conjugation), plus C07K 16/26 — describes a half-life-extension play: bolt an incretin peptide onto an antibody scaffold to make it last.

Why the structure matters to a deal desk: in metabolic medicine, durability is the franchise. A conjugate that fuses a dual agonist to an antibody is an engineering answer to the dosing-frequency problem, and engineering answers that are patented are the assets that get licensed. The conjugation chemistry, not just the peptide, is the protectable value here.

“Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the pep…”— U.S. Patent No. 10,800,826 source

The disciplined read: separate the molecule from the delivery. This grant claims a way of presenting a dual agonist, which can be licensed independently of any single clinical candidate. For a model, that means the asset's value is partly platform — applicable across peptides — and partly program-specific. Naming the grant is how you avoid pricing the press release.

What the grant does not promise: a marketed product, a best-in-class profile, or freedom from the broader incretin IP thicket. A conjugate grant is an exclusivity claim on a construction method, not a clinical result. Those live in separate filings.

The takeaway: when valuing a metabolic deal, read the conjugation and half-life claims as carefully as the peptide claims. Merck's October 2020 grant is a dated, issued example of the dual-agonism-plus-durability bet that the whole sector has since chased.